| Document |
Document Title |
|
WO/2020/213568A1 |
Disclosed is a method for producing a polymerized polypeptide aggregate, said method comprising a step for reacting a polypeptide, which has a tag on the N-terminal side and/or C-terminal side, with a polymerase to give a reaction liquid...
|
|
WO/2020/203626A1 |
The present invention provides a biologically-related substance to which a branched degradable polyethylene glycol derivative being decomposed in cells and being represented by formula (A) below is bound. (In the formula, each symbol is ...
|
|
WO/2020/195302A1 |
Provided is a linker molecule for producing a cell membrane-permeable ring-shaped peptide, the linker molecule having a cell membrane permeability-imparting group; and a ring-forming group which forms a peptide into a ring shape.
|
|
WO/2020/198644A1 |
The present disclosure is directed to physical mixtures of diblock copolypeptide hydrogel (DCH) systems. These systems exhibit mechanical strength and stiffness that are synergistically increased over the individual component DCHs, to gr...
|
|
WO/2020/158687A1 |
In the present invention, a method for producing a compound of formula I comprises a step for causing a compound of formula III to undergo a Pechmann condensation reaction with respect to a compound of formula II in the presence of an or...
|
|
WO/2020/125307A1 |
Disclosed is a method for constructing a Pseudomonas aeruginosa O11 serotype O antigen oligosaccharide using a D-glucose block, a L-fucosamine block and a D-fucosamine block, wherein the D-glucose block or the L-fucosamine block is conne...
|
|
WO/2020/112647A1 |
This document relates to using bidirectional, multi-enzymatic scaffolds to biosynthesize cannabinoids in recombinant hosts.
|
|
WO/2020/097188A1 |
Disclosed herein are compositions and methods for the identification of molecules capable of repressing NK-mediated killing of a target (donor) cell. The invention comprises the development and use of an assay to detect the effects of ta...
|
|
WO/2020/077136A1 |
Charged polypeptides, their conjugates, and fusion proteins comprising such polypeptides are disclosed. Inclusion of such a polypeptide in a fusion protein increases the protein's properties such as stability and circulation half-life, w...
|
|
WO/2020/058889A1 |
The present patent application relates to the use of an innovative amino acid derivative of glucosamine having the Formula 1 of the general structure which follows, or of a pharmaceutical composition which contains it as a single active ...
|
|
WO/2020/052677A1 |
There is provided a peptide-containing compound that comprises a peptide component which is an amino acid sequence of from 2 to 45 amino acids, which peptide component is covalently bonded to one or more compounds of the formula (I), whe...
|
|
WO/2020/051566A1 |
Although numerous investigations are focused on developing vaccines that induce protective humoral responses, fewer studies are aimed at developing vaccines that induce broad and robust T cell responses. In order to design a potent T cel...
|
|
WO/2020/039984A1 |
The present invention addresses the problem of providing a compound library which has a higher percentage of biologically active compounds. This problem is solved by a compound library that includes cyclic peptides that comprise (i) an a...
|
|
WO/2020/028744A1 |
Disclosed herein are chimeric receptors and precursors, chimeric antigen receptors and precursors, universal chimeric receptor cell precursors, chimeric antigen receptor T cells, and methods of constructing and using the same.
|
|
WO/2020/004810A1 |
The present invention relates to a method for preparing a poly-γ-glutamic acid hydrogel by using ultraviolet rays, and a use of a poly-γ-glutamic acid hydrogel prepared by the preparation method. The method for preparing a poly-γ-glut...
|
|
WO/2019/246392A1 |
The present disclosure provides a cytokine-based bioactivatable drug construct ("VitoKine") platform that aims to reduce systemic mechanism-based toxicities and lead to broader therapeutic utility for proteins and cytokines such as IL-15...
|
|
WO/2019/240288A1 |
The present invention provides art that enables modification of an antibody, particularly regioselective modification of an antibody. More specifically, the present invention provides a substance having affinity for an antibody, and a co...
|
|
WO/2019/199733A1 |
Provided herein are compositions and methods for treating cancer. In particular, provided herein are compositions, methods, and uses of inhibitors of ARlnc1 for treating cancer.
|
|
WO/2019/195859A1 |
The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for trea...
|
|
WO/2019/176860A1 |
This cell adhesive material is obtained by modifying a substrate surface by using a peptide group comprising a peptide that contains: 40% to 75%, inclusive, of one or more types of basic amino acid residues selected from the group consis...
|
|
WO/2019/135233A1 |
Disclosed herein is a process of preparing a polypeptide copolymer by polymerizing a mixture comprising N-carboxyanhydrides of alanine, tyrosine, carboxylate-protected glutamate and an amine-protected lysine, to form a protected polypept...
|
|
WO/2019/117274A1 |
With regard to the present invention, it was discovered that a deprotection agent can be deactivated by a salt formed from a base and an acid having characteristics (i) and (ii), and as a result, excessive elongation of a peptide can be ...
|
|
WO/2019/114159A1 |
A Camellia Oleifera meal polypeptide as well as a preparation method and an application thereof. The Camellia Oleifera meal polypeptide is prepared by taking Camellia Meiocarpa Hu. meal as raw materials, hydrolyzing the Camellia Meiocarp...
|
|
WO/2019/110774A1 |
The invention relates to a composition in the form of an injectable aqueous solution having a pH of between 6.0 and 8.0 and comprising at least: a basal insulin having an isoelectric point (pI) of between 5.8 and 8.5; b) and a co-polyami...
|
|
WO/2019/110797A1 |
The invention relates to a composition in the form of an injectable aqueous solution having a pH of between 6.0 and 8.0 and comprising at least: • a) amylin, an amylin receptor agonist or an amylin analog; • b) a co-polyamino acid be...
|
|
WO/2019/102469A1 |
Anti-fogging proteinoid compounds are disclosed. Processes of preparing antifogging proteinoid compositions and incorporating thereof in or on a substrate are disclosed. Articles of manufacturing incorporating such compositions are also ...
|
|
WO/2019/088167A1 |
Provided is a purification agent which comprises a compound having a betaine structure, and which is for a sugar chain having a length equal to or longer than that of a monosaccharide or for a glycopeptide having a sugar chain having a l...
|
|
WO/2019/046699A1 |
The invention includes a bioelectronic interface comprising a self-assembling unit, wherein the self-assembling unit comprises a variant GPCR fusion protein bound to an S-layer fusion protein. The invention also encompasses a biosensor o...
|
|
WO/2019/031446A1 |
[Problem] To provide a method and a composition for enhancing the immunogenicity of a polypeptide. [Solution] Provided is a composition containing a tagged polypeptide which is composed of a polypeptide, a spacer peptide bonded to a term...
|
|
WO/2019/018238A1 |
In certain embodiments osteoadsorptive fluorogenic substrates of cathepsin K (or other proteases) are provided. Utilizing a bisphosphonate targeting moiety, the fluorogenic substrates provide effective bone-targeted protease sensor(s). I...
|
|
WO/2018/225864A1 |
The present inventors found that, in screening a cyclic peptide compound capable of specifically binding to a target molecule, the hitting rate of a cyclic peptide compound capable of specifically binding to the target molecule can be im...
|
|
WO/2018/159797A1 |
The present invention addresses the problem of providing: an embedding agent for a cell mass or a cell structure which allows the cell mass or the cell structure to be stably transported during transportation at low temperature, and allo...
|
|
WO/2017/124921A9 |
The present invention provides a walnut oligopeptide powder, and a preparation method and application thereof. The oligopeptide powder has a peptide content of 80 wt% or higher, wherein 95% or more of the peptides have a molecular weight...
|
|
WO/2018/140974A1 |
Disclosed herein are methods, reagents, and pharmaceutical compositions for modulating immune effector cell activation that does not requirean antigen-specific antibody. The IgG Fc region is shown herein to contain both a domain that bin...
|
|
WO/2018/088455A1 |
To develop a novel biomarker that is useful in diagnosing sepsis and provide a diagnostic agent and diagnostic method therefor. A method for diagnosing sepsis, said method comprising measuring a component selected from carbonic anhydrase...
|
|
WO/2018/088541A1 |
The present invention provides a drug release means that is capable of independently controlling release of two or more kinds of drugs by supporting the drugs by a hydrogel which contains micelles of a cationic block polypeptide and mice...
|
|
WO/2018/085846A1 |
The invention relates to multi-functional antibiotic agents formed from antibiotics conjugated to microbial membrane disrupting peptides. These antibiotic-peptide conjugates are designed so that the conjugate simultaneously functions as ...
|
|
WO/2018/075885A1 |
Supramolecular structures comprising noncovalently associated peptide amphiphiles and lipids are provided. In particular, provided herein are supramolecular nanostructures of peptide amphiphiles and lipids, co-assembly of which is driven...
|
|
WO/2018/057858A1 |
Molecular determinants of cancer response to immunotherapy are described, as are systems and tools for identifying and/or characterizing cancers likely to respond to immunotherapy.
|
|
WO/2018/042423A1 |
The present invention provides an improved process for preparing microparticles containing glatiramer acetate having low levels of residual organic solvent(s), in particular dichloromethane. The microparticles are incorporated into long ...
|
|
WO/2018/023028A1 |
Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with synucleinopathy and for measuring synucleinopathy progression or status. Test kits for diagnosis of an indiv...
|
|
WO/2018/014841A1 |
A self-assembled collagen and a preparation method therefor. The preparation method for the self-assembled collagen comprises the following steps: utilizing trypsin and papain in an enzymatic treatment of an animal-derived collagen so as...
|
|
WO/2018/005608A1 |
In an aspect of the present application, compositions and methods are provided for preventing bone loss and/or stimulating bone healing in a subject in need thereof. Compositions can comprise a pharmaceutically acceptable carrier and a t...
|
|
WO/2017/213158A1 |
The present invention addresses the problem of providing: a ribosome complex which can be prepared without involving a complicated reaction procedure, and in which a presented polypeptide is modified without impairing the function of a r...
|
|
WO/2017/214076A1 |
The present invention describes rhomboid protease inhibitors having high specificity and inhibition characteristics providing novel antibiotics, anti-malarial pharmaceutical agents, and provides a strategy for designing RiBns (rhomboid-i...
|
|
WO/2016/176649A9 |
The present, invention provides a process for characterizing a glatiramer acetate related drug substance (GARDS) or a glatiramer acetate related drug product (GARDP) comprising separating a batch of a GARDS or GARDP according to hydropho...
|
|
WO/2017/185250A1 |
Provided in the present application is a peptide containing the amino acid sequence YEKLTTLDTGGV (SEQ ID NO:1) or a functional variant thereof, the peptide being an active peptide for treating central nervous system injury. Also provided...
|
|
WO/2017/181979A1 |
Disclosed is a mussel mucin or applications thereof in inhibiting organ inflammation. Specifically disclosed is the mussel mucin or the applications thereof in treating inflammation of the heart, stomach, intestines, lungs, liver, spleen...
|
|
WO/2017/167870A1 |
The invention concerns a synthetic compound for enabling transfection of eukaryotic cells by means of an amphiphilic block copolymer which synthetic compound comprises a peptide residue having at least one targeting sequence and a nuclei...
|
|
WO/2017/173356A1 |
Methods and apparatus for identifying and screening hydrogen bond networks are provided. A computing device can determine a search space for hydrogen bond networks related to one or more molecules, where the search space can include a pl...
|
